A Phase III, Randomized, Open Label Study Evaluating the Safety and Efficacy of Apixaban in Subjects With Cancer Related Venous Thromboembolism

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism »